2014 Program


Monday, 21 April

  9:00-10:30am SESSION 1: Welcome and the structure and function of midkine                                   

 Moderator: Darren Jones

 9:00am-9:15am

Welcome and introduction from Symposium sponsor, Cellmid Limited Maria Halasz, CEO & Managing Director, Cellmid Limited, Sydney, Australia


 9:15am-9:20am Welcome from the Symposium hosts Emeritus Prof Takashi Muramatsu and Prof Kenji Kadomatsu, Nagoya University, Nagoya, Japan
 9:20am-10:00am

PLENARY 1: Midkine in Kyoto Emeritus Prof Takashi Muramatsu, Nagoya University, Nagoya, Japan


 10:00am-10:30am
The evolution of midkine activity: insights from structure-function analysis in teleost fish Assoc Prof Christoph Winkler, Dept. of Biological Sciences, National University of Singapore

 10:30am-11:00am

Morning tea and poster viewing

 11:00am-12:30pm SESSION 2: Malignant tumors and midkine 1                                    

 Moderator: Hideaki Shimada

 11:00am-11:30am

CLL micro-environment interactions and the role of midkine Assoc Prof Idit Shachar, Department of Immunology, Weizmann Institute of Sciences, Rehovot, Israel


 11:30am -12:00pm RNA aptamer and monoclonal antibody-mediated targeting of midkine against neuroblastoma Dr Satoshi Kishida,  Nagoya University Graduate School of Medicine, Nagoya, Japan
 12:00pm-12:30pm

Next generation sequencer-based expression analysis including the midkine family in neuroblastoma  Prof Shinya Ikematsu, Okinawa National College of Technology, Okinawa, Japan


12:30pm-2:00pm Lunch

 2:00pm-3:30pm SESSION 3:  Malignant tumors and midkine 2   

 Moderator: Masatoshi Tagawa
 2:00pm-2:30pm The midkine/ALK axis as a therapeutic target in gliomas s  Dr Guillermo Velasco, Department of Biochemistry and Molecular Biology, School of Biology, Complutense University, Madrid, Spain
 2:30pm-3:00pm ATP dependent channel blocker glibenclamide synergistically potentiates cytotoxic effect of Imatinib mesylate in human glioblastoma cell line via decreasing drug resistance and midkine levels Assoc Prof Nuray Yazihan, Department of Physiology, Faculty of Medicine, Baskent University, Ankara, Turkey 

 3:00pm-3:30pm

Midkine levels are changed in direct proportion to biphasic lithium chloride in CaP stem cells Assoc Prof Mine Erguven, İstanbul Aydın Univeristy, Faculty of Engineering, Istanbul, Turkey


 3:30pm-4:15pm

Afternoon tea and poster viewing

 4:15pm-5:15pm SESSION 4: Malignant tumors and midkine 3                                                                   

 Moderator: Guillermo Velasco

 4:15pm-4:45pm

Midkine as a serum biomarker in various cancers Prof Hideaki Shimada,  Department of Surgery, School of Medicine, Toho University, Tokyo, Japan


 4:45pm-5:15pm A new therapeutic strategy for cancer with replication-competent adenoviruses powered by the midkine promoter Prof Masatoshi Tagawa,  Division of Pathology and Cell Therapy, Chiba Cancer Centre Research Institute, Chiba, Japan

 5:30pm - 7:30pm  Welcome reception, Okura Hotel

   
 

Tuesday, 22 April

 9:00am-10:00am SESSION 5: ALK and midkine signaling
 Moderator: Kenji Kadomatsu
 9:00am-10:00am

PLENARY 2: Oncogenic ALK signaling of neuroblastoma mediated by ALK-binding molecules   Dr Ryuichi Sakai, Chief, Division of Metastasis & Invasion Signaling, National Cancer Center Research Institute, Tokyo, Japan


 10:00am-10:30am Normal and aberrant control of neurogenesis in the autonomic nervous system with focus on ALK and midkine signalling Prof Herman Rohrer, Developmental Neurobiology, Max Planck Institute for Brain Research, Frankfurt, Germany

 10:30am-11:00am

Morning tea and poster viewing

  11:00am-12:00pm SESSION 6: The nervous and sensory system and midkine                          

 Moderator: Herman Rohrer
 11:00-11:30am Midkine and pleiotrophin in CNS pathologies: rational design and discovery of drugs that mimic midkine effects Prof Gonzalo Herradon, Laboratory of Pharmacology and Toxicology, Univ. San Pablo, Madrid, Spain
 11:30am-12:00pm The function of midkine in the developing and adult retina Prof Peter Hitchcock, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, USA

 12:00pm-1:15pm

Lunch

1:15pm-2:45pm SESSION 7: New aspects in midkine research                               

 Moderator: Gonzalo Herradon
 1:15pm-1:45pm Midkine regulates blood pressure through multiple pathways Prof Kenji Kadomatsu, Nagoya University Graduate School of Medicine, Nagoya, Japan
 1:45pm-2:15pm The cytokine midkine supports neutrophil trafficking during acute inflammation by promoting adhesion via β2 integrins (CD11/CD18) Dr Ludwig Weckbach, Walter Brendel Centre of Experimental Medicine, Ludwig-Maximillians University, Munich, Germany
 2:15pm-2:45pm Conformational determinants of the intracellular localization of midkine Prof Dai Licheng, Huzhou Key Laboratory of Molecular Medicine, Huzhou City 313000, Zhejiang Province, China

 2:45pm-3:15pm

Afternoon tea and poster viewing

  3:15pm-4:45pm SESSION 8: The skeletal and muscular system and midkine     

 Moderator: Takashi Muramatsu
 3:15pm-3:45pm Anti-midkine antibody treatment enhances fracture healing in mice Dr Astrid Liedert, Institute of Orthopedic Research and Biomechanics, Center of Musculoskeletal Research, University of Ulm, Ulm, Germany
 3:45pm-4:15pm Recombinant human midkine promotes proliferation and type II collagen synthesis of 3D cultured human osteoarthritis chondrocytes via Erk1/2 signalling Prof Wei Han, School of Pharmacy Shanghai Jiao Tong University, Shanghai, China
 4:15pm-4:45pm Midkine-deficient mice delayed degeneration and regeneration after muscle injury Emeritus Prof Yoshihiro Yoshida, School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
 4:45pm-5:00pm Intermission

 5:00pm-6:00pm PANEL DISCUSSION: Midkine in transition: from the research lab into the clinic

 Moderator: Darren Jones
 PANELISTS: Prof Peter Ferdinandy, Pharmahungary Group, Szeged, and Semmelweis University, Budapest, Hungary; Mr Graeme Kaufman, Director, Cellmid Ltd, Sydney, Australia; Prof Pamela Russell AM, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia; Dr Nico Mertens, Vice-President and Head of Antibody Engineering Programs, Biotecnol Inc, New Jersey, USA

 7:00pm - 11:00pm  Symposium banquet River Suite Kyoto Kamogawa

   

Wednesday, 23 April

 9:00am - 1:00pm: Social activity-  sightseeing tour of Kyoto heritage sites, departs Okura Hotel